-
1
-
-
0018939225
-
Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
-
A.W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, and J. Springer Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent Proc. Natl. Acad. Sci. U. S. A. 77 1980 3957 3961
-
(1980)
Proc. Natl. Acad. Sci. U. S. A.
, vol.77
, pp. 3957-3961
-
-
Alberts, A.W.1
Chen, J.2
Kuron, G.3
Hunt, V.4
Huff, J.5
Hoffman, C.6
Rothrock, J.7
Lopez, M.8
Joshua, H.9
Harris, E.10
Patchett, A.11
Monaghan, R.12
Currie, S.13
Stapley, E.14
Albers-Schonberg, G.15
Hensens, O.16
Hirshfield, J.17
Hoogsteen, K.18
Liesch, J.19
Springer, J.20
more..
-
2
-
-
67249153214
-
Red yeast rice for dyslipidemia in statin-intolerant patients: A randomized trial
-
D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann. Intern. Med. 150 2009 830 839
-
(2009)
Ann. Intern. Med.
, vol.150
, pp. 830-839
-
-
Becker, D.J.1
Gordon, R.Y.2
Halbert, S.C.3
French, B.4
Morris, P.B.5
Rader, D.J.6
-
3
-
-
46749098263
-
Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial
-
D.J. Becker, R.Y. Gordon, P.B. Morris, J. Yorko, Y.J. Gordon, M. Li, and N. Iqbal Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial Mayo Clin. Proc. 83 2008 758 764
-
(2008)
Mayo Clin. Proc.
, vol.83
, pp. 758-764
-
-
Becker, D.J.1
Gordon, R.Y.2
Morris, P.B.3
Yorko, J.4
Gordon, Y.J.5
Li, M.6
Iqbal, N.7
-
4
-
-
0021139131
-
Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge
-
A. Chattopadhyay, and E. London Fluorimetric determination of critical micelle concentration avoiding interference from detergent charge Anal. Biochem. 139 1984 408 412
-
(1984)
Anal. Biochem.
, vol.139
, pp. 408-412
-
-
Chattopadhyay, A.1
London, E.2
-
5
-
-
15344341734
-
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1
-
C. Chen, R.J. Mireles, S.D. Campbell, J. Lin, J.B. Mills, J.J. Xu, and T.A. Smolarek Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab. Dispos. 33 2005 537 546
-
(2005)
Drug Metab. Dispos.
, vol.33
, pp. 537-546
-
-
Chen, C.1
Mireles, R.J.2
Campbell, S.D.3
Lin, J.4
Mills, J.B.5
Xu, J.J.6
Smolarek, T.A.7
-
6
-
-
84871447117
-
Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin
-
Article ID 127043
-
C.H. Chen, Y.S. Uang, S.T. Wang, J.C. Yang, and C.J. Lin Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin Evid. Based Complement. Alternat. Med. 2012 10 Article ID 127043
-
(2012)
Evid. Based Complement. Alternat. Med.
, pp. 10
-
-
Chen, C.H.1
Uang, Y.S.2
Wang, S.T.3
Yang, J.C.4
Lin, C.J.5
-
7
-
-
0031913402
-
Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
-
J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms Pharm. Res. 15 1998 11 22
-
(1998)
Pharm. Res.
, vol.15
, pp. 11-22
-
-
Dressman, J.B.1
Amidon, G.L.2
Reppas, C.3
Shah, V.P.4
-
8
-
-
0031750861
-
Evaluation of various dissolution media for predicting in vivo performance of class i and II drugs
-
E. Galia, E. Nicolaides, D. Hörter, R. Löbenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 1998 698 705
-
(1998)
Pharm. Res.
, vol.15
, pp. 698-705
-
-
Galia, E.1
Nicolaides, E.2
Hörter, D.3
Löbenberg, R.4
Reppas, C.5
Dressman, J.B.6
-
9
-
-
0032898925
-
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
-
D. Heber, I. Yip, J.M. Ashley, D.A. Elashoff, R.M. Elashoff, and V.L. Go Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement Am. J. Clin. Nutr. 69 1999 231 236
-
(1999)
Am. J. Clin. Nutr.
, vol.69
, pp. 231-236
-
-
Heber, D.1
Yip, I.2
Ashley, J.M.3
Elashoff, D.A.4
Elashoff, R.M.5
Go, V.L.6
-
10
-
-
34250620912
-
Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients
-
C.F. Huang, T.C. Li, C.C. Lin, C.S. Liu, H.C. Shih, and M.M. Lai Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients Eur. J. Cardiovasc. Prev. Rehabil. 14 2007 438 440
-
(2007)
Eur. J. Cardiovasc. Prev. Rehabil.
, vol.14
, pp. 438-440
-
-
Huang, C.F.1
Li, T.C.2
Lin, C.C.3
Liu, C.S.4
Shih, H.C.5
Lai, M.M.6
-
11
-
-
0031954328
-
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
-
T. Kantola, K.T. Kivistö, and P.J. Neuvonen Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid Clin. Pharmacol. Ther. 63 1998 397 402
-
(1998)
Clin. Pharmacol. Ther.
, vol.63
, pp. 397-402
-
-
Kantola, T.1
Kivistö, K.T.2
Neuvonen, P.J.3
-
12
-
-
67650564624
-
Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia
-
M. Klimek, S. Wang, and A. Ogunkanmi Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia P. T. 34 2009 313 327
-
(2009)
P. T.
, vol.34
, pp. 313-327
-
-
Klimek, M.1
Wang, S.2
Ogunkanmi, A.3
-
13
-
-
36549034768
-
Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
-
S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, J. Halsey, N. Qizilbash, R. Peto, and R. Collins Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
-
(2007)
Lancet
, vol.370
, pp. 1829-1839
-
-
Lewington, S.1
Whitlock, G.2
Clarke, R.3
Sherliker, P.4
Emberson, J.5
Halsey, J.6
Qizilbash, N.7
Peto, R.8
Collins, R.9
-
14
-
-
31144436097
-
Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers
-
Z. Li, N.P. Seeram, R. Lee, G. Thames, C. Minutti, H.J. Wang, and D. Heber Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers J. Altern. Complement. Med. 11 2005 1031 1038
-
(2005)
J. Altern. Complement. Med.
, vol.11
, pp. 1031-1038
-
-
Li, Z.1
Seeram, N.P.2
Lee, R.3
Thames, G.4
Minutti, C.5
Wang, H.J.6
Heber, D.7
-
15
-
-
27944482535
-
Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia
-
C.C. Lin, T.C. Li, and M.M. Lai Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia Eur. J. Endocrinol. 153 2005 679 686
-
(2005)
Eur. J. Endocrinol.
, vol.153
, pp. 679-686
-
-
Lin, C.C.1
Li, T.C.2
Lai, M.M.3
-
16
-
-
34250741897
-
Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials
-
article 4
-
J. Liu, J. Zhang, Y. Shi, S. Grimsgaard, T. Alraek, and V. Fønnebø Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials Chin. Med. 1 2006 article 4
-
(2006)
Chin. Med.
, vol.1
-
-
Liu, J.1
Zhang, J.2
Shi, Y.3
Grimsgaard, S.4
Alraek, T.5
Fønnebø, V.6
-
17
-
-
44749084870
-
Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
-
Z. Lu, W. Kou, B. Du, Y. Wu, S. Zhao, O.A. Brusco, J.M. Morgan, D.M. Capuzzi, and S. Li Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction Am. J. Cardiol. 101 2008 1689 1693
-
(2008)
Am. J. Cardiol.
, vol.101
, pp. 1689-1693
-
-
Lu, Z.1
Kou, W.2
Du, B.3
Wu, Y.4
Zhao, S.5
Brusco, O.A.6
Morgan, J.M.7
Capuzzi, D.M.8
Li, S.9
-
18
-
-
45549091043
-
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
-
P.J. Neuvonen, J.T. Backman, and M. Niemi Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin Clin. Pharmacokinet. 47 2008 463 474
-
(2008)
Clin. Pharmacokinet.
, vol.47
, pp. 463-474
-
-
Neuvonen, P.J.1
Backman, J.T.2
Niemi, M.3
-
19
-
-
33845420011
-
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
-
P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin. Pharmacol. Ther. 80 2006 565 581
-
(2006)
Clin. Pharmacol. Ther.
, vol.80
, pp. 565-581
-
-
Neuvonen, P.J.1
Niemi, M.2
Backman, J.T.3
-
20
-
-
84874341518
-
-
Merck & Co.; Inc. Whitehouse Station, NJ 08889, USA
-
Package insert of Mevacor 2012 Merck & Co.; Inc. Whitehouse Station, NJ 08889, USA http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 019643s085lbl.pdf
-
(2012)
Package Insert of Mevacor
-
-
-
21
-
-
63649143585
-
Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques
-
M. Patel, A. Tekade, S. Gattani, and S. Surana Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques AAPS PharmSciTech. 9 2008 1262 1269
-
(2008)
AAPS PharmSciTech.
, vol.9
, pp. 1262-1269
-
-
Patel, M.1
Tekade, A.2
Gattani, S.3
Surana, S.4
-
22
-
-
0036073540
-
Food-drug interactions
-
L.E. Schmidt, and K. Dalhoff Food-drug interactions Drugs 62 2002 1481 1502
-
(2002)
Drugs
, vol.62
, pp. 1481-1502
-
-
Schmidt, L.E.1
Dalhoff, K.2
-
23
-
-
0025944198
-
Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
-
A.T. Serajuddin, S.A. Ranadive, and E.M. Mahoney Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin J. Pharm. Sci. 80 1991 830 834
-
(1991)
J. Pharm. Sci.
, vol.80
, pp. 830-834
-
-
Serajuddin, A.T.1
Ranadive, S.A.2
Mahoney, E.M.3
-
24
-
-
0024396590
-
In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants
-
V.P. Shah, J.J. Konecny, R.L. Everett, B. McCullough, A.C. Noorizadeh, and J.P. Skelly In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants Pharm. Res. 6 1989 612 618
-
(1989)
Pharm. Res.
, vol.6
, pp. 612-618
-
-
Shah, V.P.1
Konecny, J.J.2
Everett, R.L.3
McCullough, B.4
Noorizadeh, A.C.5
Skelly, J.P.6
-
25
-
-
84861049705
-
A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia
-
Article ID 636547
-
Q. Shang, Z. Liu, K. Chen, H. Xu, and J. Liu A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia Evid. Based Complement. Alternat. Med. 2012 18 Article ID 636547
-
(2012)
Evid. Based Complement. Alternat. Med.
, pp. 18
-
-
Shang, Q.1
Liu, Z.2
Chen, K.3
Xu, H.4
Liu, J.5
-
26
-
-
34047232844
-
Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles
-
G. Suresh, K. Manjunath, V. Venkateswarlu, and V. Satyanarayana Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles AAPS PharmSciTech. 8 2007 E162 E170
-
(2007)
AAPS PharmSciTech.
, vol.8
-
-
Suresh, G.1
Manjunath, K.2
Venkateswarlu, V.3
Satyanarayana, V.4
-
27
-
-
84874290358
-
Dissolution test for lovastatin tablet
-
Usp United States Pharmacopeial Convention pp. 2816-2817
-
USP Dissolution test for lovastatin tablet United States Pharmacopeia National Formulary, USP32 2009 United States Pharmacopeial Convention pp. 2816-2817
-
(2009)
United States Pharmacopeia National Formulary, USP32
-
-
-
28
-
-
0025944905
-
Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
-
R.W. Wang, P.H. Kari, A.Y. Lu, P.E. Thomas, F.P. Guengerich, and K.P. Vyas Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes Arch. Biochem. Biophys. 290 1991 355 361
-
(1991)
Arch. Biochem. Biophys.
, vol.290
, pp. 355-361
-
-
Wang, R.W.1
Kari, P.H.2
Lu, A.Y.3
Thomas, P.E.4
Guengerich, F.P.5
Vyas, K.P.6
-
29
-
-
78650180318
-
Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs
-
C. Wu, Z. Wang, Z. Zhi, T. Jiang, J. Zhang, and S. Wang Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs Int. J. Pharm. 403 2011 162 169
-
(2011)
Int. J. Pharm.
, vol.403
, pp. 162-169
-
-
Wu, C.1
Wang, Z.2
Zhi, Z.3
Jiang, T.4
Zhang, J.5
Wang, S.6
-
30
-
-
17644380257
-
Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system
-
C.Y. Wu, and L.Z. Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22 2005 11 23
-
(2005)
Pharm. Res.
, vol.22
, pp. 11-23
-
-
Wu, C.Y.1
Benet, L.Z.2
-
31
-
-
33847223472
-
Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: Subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention study (CCSPS)
-
S.P. Zhao, Z.L. Lu, B.M. Du, Z. Chen, Y.F. Wu, X.H. Yu, Y.C. Zhao, L. Liu, H.J. Ye, and Z.H. Wu Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention study (CCSPS) J. Cardiovasc. Pharmacol. 49 2007 81 84
-
(2007)
J. Cardiovasc. Pharmacol.
, vol.49
, pp. 81-84
-
-
Zhao, S.P.1
Lu, Z.L.2
Du, B.M.3
Chen, Z.4
Wu, Y.F.5
Yu, X.H.6
Zhao, Y.C.7
Liu, L.8
Ye, H.J.9
Wu, Z.H.10
|